Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis

Journal of Clinical Investigation

Volumn 115, Issue 12, 2005, Pages 3594-3601

  Kirimanjeswara, Girish S ^a   Agosto, Luis M ^a   Kennett, Mary J ^a   Bjornstad, Ottar N ^a   Harvill, Eric T ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; PERTUSSIS TOXIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BACTERIUM MUTANT; BORDETELLA PERTUSSIS; CELL COUNT; CELL MIGRATION; CONTROLLED STUDY; IMMUNITY; LUNG; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OPSONIZATION; PERTUSSIS; PHAGOCYTOSIS; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, BACTERIAL; AORTA; BORDETELLA INFECTIONS; BORDETELLA PERTUSSIS; CELL MOVEMENT; CHEMOKINES; CYTOKINES; ENDOTHELIUM, VASCULAR; HUMANS; LEUKOCYTES; LUNG; MICE; MICE, INBRED C57BL; MUTATION; NEUTROPHILS; PERTUSSIS TOXIN; PHAGOCYTOSIS; RECEPTORS, FC; RECEPTORS, IGG; TIME FACTORS; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 31044445642     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI24609     Document Type: Article

References (68)

1. Cherry, J.D. 1984. The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United States: a comparative study. Curr. Probl. Pediatr. 14:1-78.
2. Cherry, J.D., Brunell, P.A., Golden, G.S., and Karson, D.T. 1988. Report of the task force on pertussis and pertussis immunization-1988. Pediatrics. 81(Suppl.):939-984.
3. Cherry, J.D., and Heininger, U. 2004. Pertussis and other Bordetella infections. In Textbook of pediatric infectious diseases. W.B. Saunders. Philadelphia, Pennsylvania, USA. 1588-1608.
4. Gilberg, S., et al. 2002. Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a French area with very high whole-cell vaccine coverage. J. Infect. Dis. 186:415-418.
5. Hodder, S.L., et al. 2000. Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents. Clin. Infect. Dis. 31:7-14.
6. Nennig, M.E., Shinefield, H.R., Edwards, K.M., Black, S.B., and Fireman, B.H. 1996. Prevalence and incidence of adult pertussis in an urban population. JAMA. 275:1672-1674.
7. Schmitt-Grohe, S., et al. 1995. Pertussis in German adults. Clin. Infect. Dis. 21:860-866.
8. Wright, S.W., Edwards, K.M., Decker, M.D., and Zeldin, M.H. 1995. Pertussis infection in adults with persistent cough. JAMA. 273:1044-1046.
9. Deville, J.G., et al. 1995. Frequency of unrecognized Bordetella pertussis infections in adults. Clin. Infect. Dis. 21:639-642.
10. Deen, J.L., et al. 1995. Household contact study of Bordetella pertussis infections. Clin. Infect. Dis. 21:1211-1219.
11. Cherry, J.D., et al. 1995. Comparison of values of antibody to Bordetella pertussis antigens in young German and American men. Clin. Infect. Dis. 20:1271-1274.
12. Crowcroft, N.S., et al. 2003. Severe and unrecognised: pertussis in UK infants. Arch. Dis. Child. 88:802-806.
13. Baron, S., et al. 1998. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr. Infect. Dis. J. 17:412-418.
14. Bisgard, K.M., et al. 2004. Infant pertussis: who was the source? Pediatr. Infect. Dis. J. 23:985-989.
15. Cherry, J.D., Gornbein, J., Heininger, U., and Stehr, K. 1998. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 16:1901-1906.
16. Storsaeter, J., Hallander, H.O., Gustafsson, L., and Olin, P. 1998. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 16:1907-1916.
17. Long, S.S., Welkon, C.J., and Clark, J.L. 1990. Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. J. Infect. Dis. 161:480-486.
18. Leef, M., Elkins, K.L., Barbic, J., and Shahin, R.D. 2000. Protective immunity to Bordetella pertussis requires both B cells and CD4(+) T cells for key functions other than specific antibody production. J. Exp. Med. 191:1841-1852.
19. Mahon, B.P., Sheahan, B.J., Griffin, F., Murphy, G., and Mills, K.H. 1997. Atypical disease after Bordetella pertussis respiratory infection of mice with targeted disruptions of interferon-gamma receptor or immunoglobulin mu chain genes. J. Exp. Med. 186:1843-1851.
20. Kirimanjeswara, G.S., Mann, P.B., and Harvill, E.T. 2003. Role of antibodies in immunity to Bordetella infections. Infect. Immun. 71:1719-1724.
21. King, A.J., et al. 2001. Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology. 147:2885-2895.
22. Musser, J.M., Hewlett, E.L., Peppler, M.S., and Selander, R.K. 1986. Genetic diversity and relationships in populations of Bordetella spp. J. Bacteriol. 166:230-237.
23. van der Zee, A., Mooi, F., Van Embden, J., and Musser, J. 1997. Molecular evolution and host adaptation of Bordetella spp.: phylogenetic analysis using multilocus enzyme electrophoresis and typing with three insertion sequences. J. Bacteriol. 179:6609-6617.
24. Parkhill, J., et al. 2003. Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat. Genet. 35:32-40.
25. Pishko, E.J., et al. 2004. Antibody-mediated bacterial clearance from the lower respiratory tract of mice requires complement component C3. Eur. J. Immunol. 34:184-193.
26. Kirimanjeswara, G.S., et al. 2005. The complex mechanism of antibody-mediated clearance of Bordetella from the lungs requires TLR4. J. Immunol. In press.
27. Moss, J., et al. 1983. Activation by thiol of the latent NAD glycohydrolase and ADP-ribosyltransferase activities of Bordetella pertussis toxin (islet-activating protein). J. Biol. Chem. 258:11879-11882.
28. Murayama, T., Katada, T., and Ui, M. 1983. Guanine nucleotide activation and inhibition of adenylate cyclase as modified by islet-activating protein, pertussis toxin, in mouse 3T3 fibroblasts. Arch. Biochem. Biophys. 221:381-390.
29. Spangrude, G.J., Sacchi, F., Hill, H.R., Van Epps, D.E., and Daynes, R.A. 1985. Inhibition of lymphocyte and neutrophil chemotaxis by pertussis toxin. J. Immunol. 135:4135-4143.
30. Brito, G.A., et al. 1997. Role of pertussis toxin A subunit in neutrophil migration and vascular permeability. Infect. Immun. 65:1114-1118.
31. Meade, B.D., Kind, P.D., and Manclark, C.R. 1984. Lymphocytosis-promoting factor of Bordetella pertussis alters mononuclear phagocyte circulation and response to inflammation. Infect. Immun. 46:733-739.
32. Hewlett, E.L. 1999. A commentary on the pathogenesis of pertussis. Clin. Infect. Dis. 28(Suppl. 2): S94-S98.
33. Cherry, J.D. 1997. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr. Infect. Dis. J. 16(4 Suppl.):S90-S96.
34. Taranger, J., et al. 2001. Mass vaccination of children with pertussis toxoid - decreased incidence in both vaccinated and nonvaccinated persons. Clin. Infect. Dis. 33:1004-1010.
35. Ravetch, J.V. 1997. Fc receptors. Curr. Opin. Immunol. 9:121-125.
36. Harvill, E.T., Cotter, P.A., and Miller, J.F. 1999. Pregenomic comparative analysis between bordetella bronchiseptica RB50 and Bordetella pertussis tohama I in murine models of respiratory tract infection. Infect. Immun. 67:6109-6118.
37. Conlan, J.W. 1997. Critical roles of neutrophils in host defense against experimental systemic infections of mice by Listeria monocytogenes, Salmonella typhimurium, and Yersinia enterocolitica. Infect. Immun. 65:630-635.
38. Seiler, P., et al. 2000. Rapid neutrophil response controls fast-replicating intracellular bacteria but not slow-replicating Mycobacterium tuberculosis. J. Infect. Dis. 181:671-680.
39. Carbonetti, N.H., Artamonova, G.V., Mays, R.M., and Worthington, Z.E. 2003. Pertussis toxin plays an early role in respiratory tract colonization by Bordetella pertussis. Infect. Immun. 71:6358-6366.
40. McGuirk, P., and Mills, K.H. 2000. A regulatory role for interleukin 4 in differential inflammatory responses in the lung following infection of mice primed with Th1- or Th2-inducing pertussis vaccines. Infect. Immun. 68:1383-1390.
41. Belcher, C.E., et al. 2000. The transcriptional responses of respiratory epithelial cells to Bordetella pertussis reveal host defensive and pathogen counter-defensive strategies. Proc. Natl. Acad. Sci. U. S. A. 97:13847-13852.
42. Agarwal, R.K., Sun, S.H., Su, S.B., Chan, C.C., and Caspi, R.R. 2002. Pertussis toxin alters the innate and the adaptive immune responses in a pertussis-dependent model of autoimmunity. J. Neuroimmunol. 129:133-140.
43. Shen, W., Bendall, L.J., Gottlieb, D.J., and Bradstock, K.F. 2001. The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow. Exp. Hematol. 29:1439-1447.
44. Pizza, M., et al. 1989. Mutants of pertussis toxin suitable for vaccine development. Science. 246:497-500.
45. Carbonetti, N.H., et al. 2004. Suppression of serum antibody responses by pertussis toxin after respiratory tract colonization by Bordetella pertussis and identification of an immunodominant lipoprotein. Infect. Immun. 72:3350-3358.
46. Nencioni, L., et al. 1990. Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough. Infect. Immun. 58:1308-1315.
47. Ausiello, C.M., et al. 2002. Native and genetically inactivated pertussis toxins induce human dendritic cell maturation and synergize with lipopolysaccharide in promoting T helper type 1 responses. J. Infect. Dis. 186:351-360.
48. Bokoch, G.M., and Gilman, A.G. 1984. Inhibition of receptor-mediated release of arachidonic acid by pertussis toxin. Cell. 39:301-308.
49. Katada, T., Tamura, M., and Ui, M. 1983. The A protomer of islet-activating protein, pertussis toxin, as an active peptide catalyzing ADP-ribosylation of a membrane protein. Arch. Biochem. Biophys. 224:290-298.
50. Boldrick, J.C., et al. 2002. Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc. Natl. Acad. Sci. U. S. A. 99:972-977.
51. Smith, M.L., Olson, T.S., and Ley, K. 2004. CXCR2-and E-selectin-induced neutrophil arrest during inflammation in vivo. J. Exp. Med. 200:935-939.
52. Miller, L.A., Usachenko, J., McDonald, R.J., and Hyde, D.M. 2000. Trafficking of neutrophils across airway epithelium is dependent upon both thioredoxin- and pertussis toxin-sensitive signaling mechanisms. J. Leukoc. Biol. 68:201-208.
53. Lawrence, G.L., MacIntyre, C.R., Hull, B.P., and McIntyre, P.B. 2003. Measles vaccination coverage among five-year-old children: implications for disease elimination in Australia. Aust. N. Z. J. Public Health. 27:413-418.
54. Glass, K., and Grenfell, B.T. 2004. Waning immunity and subclinical measles infections in England. Vaccine. 22:4110-4116.
55. Bolker, B.M., and Grenfell, B.T. 1993. Chaos and biological complexity in measles dynamics. Proc. Biol. Sci. 251:75-81.
56. Keeling, M.J., and Grenfell, B.T. 1997. Disease extinction and community size: modeling the persistence of measles. Science. 275:65-67.
57. Bjornstad, O.N., Peltonen, M., Liebhold, A.M., and Baltensweiler, W. 2002. Waves of larch budmoth outbreaks in the European alps. Science. 298:1020-1023.
58. Finkenstadt, B.F., Bjornstad, O.N., and Grenfell, B.T. 2002. A stochastic model for extinction and recurrence of epidemics: estimation and inference for measles outbreaks. Biostatistics. 3:493-510.
59. Storsaeter, J., Hallander, H.O., Gustafsson, L., and Olin, P. 2003. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine. 21:3542-3549.
60. Taranger, J., et al. 2001. Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine. Pediatrics. 108:E115.
61. Le, T., et al. 2004. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J. Infect. Dis. 190:535-544.
62. Robbins, J.B., et al. 2005. The diphtheria and pertussis components of diphtheria-tetanus toxoidspertussis vaccine should be genetically inactivated mutant toxins. J. Infect. Dis. 191:81-88.
63. Hausman, S.Z., and Burns, D.L. 2000. Use of pertussis toxin encoded by ptx genes from Bordetella bronchiseptica to model the effects of antigenic drift of pertussis toxin on antibody neutralization. Infect. Immun. 68:3763-3767.
64. Circolo, A., et al. 1999. Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. Immunopharmacology. 42:135-149.
65. Hodge, L.M., and Simecka, J.W. 2002. Role of upper and lower respiratory tract immunity in resistance to Mycoplasma respiratory disease. J. Infect. Dis. 186:290-294.
66. Mbawuike, I.N., and Herscowitz, H.B. 1989. MH-S, a murine alveolar macrophage cell line: morphological, cytochemical, and functional characteristics. J. Leukoc. Biol. 46:119-127.
67. Rubin-Bejerano, I., Fraser, I., Grisafi, P., and Fink, G.R. 2003. Phagocytosis by neutrophils induces an amino acid deprivation response in Saccharomyces cerevisiae and Candida albicans. Proc. Natl. Acad. Sci. U. S. A. 100:11007-11012.
68. Laichalk, L.L., et al. 1998. Intrapulmonary delivery of tumor necrosis factor agonist peptide augments host defense in murine gram-negative bacterial pneumonia. Infect. Immun. 66:2822-2826.